AbbVie Inc. (ABBV)

• Annual Data
• Quarterly Data

AbbVie Inc., Consolidated Statement of Cash Flows

USD $ in millions

	12 months ended	Dec 31, 2017		Dec 31, 2016		Dec 31, 2015		Dec 31, 2014		Dec 31, 2013
	Net earnings
	Depreciation
	Amortization of intangible assets
	Change in fair value of contingent consideration liabilities
	Stock-based compensation
	Upfront costs and milestones related to collaborations
	Devaluation loss related to Venezuela
	Intangible asset impairment
	Impacts related to U.S. tax reform
	Other, net
	Accounts receivable
	Inventories
	Prepaid expenses and other assets
	Accounts payable and other liabilities
	Changes in operating assets and liabilities, net of acquisitions
	Adjustments to reconcile net earnings to net cash from operating activities
	Cash flows from operating activities
	Acquisition of businesses, net of cash acquired
	Other acquisitions and investments
	Acquisitions of property and equipment
	Purchases of investment securities
	Sales and maturities of investment securities
	Other
	Cash flows from investing activities
	Net change in short-term borrowings
	Proceeds from issuance of long-term debt
	Repayments of long-term debt and lease obligations
	Debt issuance cost
	Dividends paid
	Purchases of treasury stock
	Proceeds from the exercise of stock options
	Payments of contingent consideration liabilities
	Net transactions with Abbott Laboratories, excluding non-cash items
	Other, net
	Cash flows from financing activities
	Effect of exchange rate changes on cash and equivalents
	Net change in cash and equivalents
	Cash and equivalents, beginning of year
	Cash and equivalents, end of year

Based on: 10-K (filing date: 2018-02-16), 10-K (filing date: 2017-02-17), 10-K (filing date: 2016-02-19), 10-K (filing date: 2015-02-20), 10-K (filing date: 2014-02-21).